Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company”, a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, announced that its Board of Directors has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-4.
